Log In
BCIQ
Print this Print this
 

Cerdulatinib (PRT062070, PRT2070)

  Manage Alerts
Collapse Summary General Information
Company Portola Pharmaceuticals Inc.
DescriptionDual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK)
Molecular Target Spleen tyrosine kinase (SYK) ; Janus kinase (JAK)
Mechanism of ActionKinase inhibitor; Syk kinase inhibitor; Janus kinase inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today